Coronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy.

Am Heart J Plus

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States of America.

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Clinical trials commonly use Cox proportional hazards models, which may be inaccurate when evaluating procedural interventions. Restricted mean survival time (RMST) is an alternative outcome measure that quantifies treatment effects without assuming proportional hazards.

Methods: We determined outcomes based on RMST in the Surgical Treatment for Ischemic Heart Failure (STICH) trial, an international multicenter randomized clinical trial comparing coronary artery bypass grafting (CABG) plus optimal medical therapy to optimal medical therapy alone in patients with ischemic cardiomyopathy.

Results: For the primary endpoint of all-cause mortality, CABG plus medical therapy was superior to medical therapy alone at 10 years of follow up when using measures of RMST. In subgroup analyses evaluating all-cause mortality, there was a greater beneficial effect of CABG for racial/ethnic minorities vs. white patients.

Conclusions: These findings reinforce the benefit of CABG and can be used to help quantify anticipated outcomes for patients with ischemic cardiomyopathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142554PMC
http://dx.doi.org/10.1016/j.ahjo.2025.100538DOI Listing

Publication Analysis

Top Keywords

medical therapy
16
patients ischemic
12
coronary artery
8
artery bypass
8
restricted survival
8
survival time
8
ischemic cardiomyopathy
8
optimal medical
8
all-cause mortality
8
bypass surgery
4

Similar Publications

Aims: To assess self-reported practices and knowledge of nurses and prescribers (i.e., physicians and nurse practitioners) on intravenous fluid therapy, and to evaluate how this is documented through a clinical documentation review.

View Article and Find Full Text PDF

Objective: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.

Methods: A cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90 percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated.

View Article and Find Full Text PDF

Wild-type p53 overexpression in -mutated acute myeloid leukemia: potential implications for disease biology and therapy response.

Haematologica

September 2025

Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, NY; Multiparametric In Situ Imaging (MISI) Laboratory, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York.

Not available.

View Article and Find Full Text PDF

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and lymphadenopathy. Two major clinical subtypes, idiopathic plasmacytic lymphadenopathy (iMCD-IPL) and iMCD with thrombocytopenia, anasarca, fever, renal dysfunction/reticulin fibrosis, and organomegaly (iMCD-TAFRO), exhibit distinct pathophysiologic mechanisms. While interleukin-6 (IL-6) is known to be elevated in iMCD, the differences in IL-6 production sources between subtypes remain unclear.

View Article and Find Full Text PDF

Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.

Haematologica

September 2025

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke.

Patient age might influence donor selection priorities in allogeneic hematopoietic stem cell transplantation (allo-HCT), due to the differences in donor age, organ function, and resistance to graft-versus-host disease between younger and older patients. We compared the transplant outcomes among human leukocyte antigen (HLA)-matched related donors (M-RDs, n=4,106), HLA 1-antigen-mismatched related donors (1MM-RDs, n=592), HLA 2-3-antigen-mismatched related donors (23MM-RDs, n=882), HLA-matched unrelated donors (M-UDs, n=3,927), HLA 1-locus-mismatched unrelated donors (1MM-UDs, n=2,474), and unrelated cord blood units (U-CBs, n=5,867) between patients aged.

View Article and Find Full Text PDF